EDM 3

EDM III was a clinical-stage biopharmaceutical company focused on the development of novel treatments for women's health conditions, specifically endometriosis and uterine fibroids. The company's lead candidate, EDM-3, was an orally active, non-peptide gonadotropin-releasing hormone (GnRH) antagonist designed to provide a more tolerable alternative to existing injectable therapies. By modulating the GnRH receptor, the therapy aimed to suppress estrogen production to therapeutic levels without the severe side effects associated with complete estrogen deprivation. The company was eventually acquired, and its lead assets were integrated into the pipeline of the acquiring entity to further clinical development.